MetaCap

Amneal Pharmaceuticals (AMRX) vs Protagonist Therapeutics (PTGX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Amneal Pharmaceuticals (AMRX) has outperformed Protagonist Therapeutics (PTGX) over the past year, gaining 76.7% versus a gain of 42.2%. Over five years, AMRX leads with a +396.9% price change compared with +265.0% for PTGX. Protagonist Therapeutics is the larger company by market cap ($7.92 billion vs $7.36 billion), about 1.1 times the size, while Amneal Pharmaceuticals is growing revenue faster (+8.0% vs -89.4%).

On valuation, Amneal Pharmaceuticals trades at a lower forward P/E (17.1x vs 348.8x for Protagonist Therapeutics). Amneal Pharmaceuticals converts more of its revenue into profit, with a net margin of 2.4% versus -282.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AMRX+76.74%PTGX+42.15%
+90%+40%-11%
Nov 21, 20251 yearNov 20, 2026
AMRX+357.14%PTGX+246.56%
+388%+143%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AMRX versus PTGX key metrics
MetricAMRXPTGX
Share price$21.12$121.40
Market cap$7.36B$7.92B
1-day change-1.26%-2.11%
YTD return+67.62%+39.00%
1-year return+76.74%+42.15%
5-year return+396.94%+265.00%
P/E ratio (TTM)52.8025.67
Forward P/E17.13348.79
EPS (TTM)$0.40$4.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$3.02B$46.02M
Revenue growth (YoY)+8.05%-89.41%
Net income (latest FY)$72.06M$-130.15M
Gross margin36.88%—
Operating margin13.05%-343.63%
Net margin2.39%-282.83%
52-week high$22.13$160.81
52-week low$11.71$77.00
Distance from 52-week high-4.54%-24.51%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+15.01%+50.21%
Average volume3.16M668.45K
Shares outstanding348.41M65.27M
Employees8,700149
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • AMRX has outperformed PTGX by 34.6 percentage points over the past year.
  • Amneal Pharmaceuticals trades at a higher earnings multiple (52.8x vs 25.7x trailing P/E).
  • Amneal Pharmaceuticals is more profitable, keeping 2.4 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
  • Amneal Pharmaceuticals grew revenue faster in its latest fiscal year (+8.05% vs -89.41%).

About Amneal Pharmaceuticals

AMRX stock →

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE.

Health Care · Biotechnology: Pharmaceutical Preparations · 8,700 employees

About Protagonist Therapeutics

PTGX stock →

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 149 employees

AMRX vs PTGX FAQ

Which is bigger, Amneal Pharmaceuticals or Protagonist Therapeutics?

Protagonist Therapeutics (PTGX) is larger, with a market capitalization of $7.92B compared with $7.36B for Amneal Pharmaceuticals (AMRX).

Which stock has performed better over the past year, AMRX or PTGX?

AMRX returned +76.74% over the past 12 months, compared with +42.15% for PTGX (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AMRX or PTGX?

PTGX has the lower trailing P/E at 25.7, versus 52.8 for AMRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Amneal Pharmaceuticals and Protagonist Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons